IS5183A - A method of enhancing the antineoplastic activity of unprocessed drugs, a mixture that enhances the anti-neoplastic activity of an unprocessed drug, a method of assessing the anti-neoplastic efficacy of the treatment of an unfinished drug, and a method of assessing the anti-tumor efficacy of an unfinished drug. - Google Patents

A method of enhancing the antineoplastic activity of unprocessed drugs, a mixture that enhances the anti-neoplastic activity of an unprocessed drug, a method of assessing the anti-neoplastic efficacy of the treatment of an unfinished drug, and a method of assessing the anti-tumor efficacy of an unfinished drug.

Info

Publication number
IS5183A
IS5183A IS5183A IS5183A IS5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A
Authority
IS
Iceland
Prior art keywords
drug
unfinished
assessing
unprocessed
neoplastic
Prior art date
Application number
IS5183A
Other languages
Icelandic (is)
Inventor
Niwa Kozo
Original Assignee
Niwa Kozo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niwa Kozo filed Critical Niwa Kozo
Publication of IS5183A publication Critical patent/IS5183A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/071—Agaricus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IS5183A 1998-09-17 1999-09-17 A method of enhancing the antineoplastic activity of unprocessed drugs, a mixture that enhances the anti-neoplastic activity of an unprocessed drug, a method of assessing the anti-neoplastic efficacy of the treatment of an unfinished drug, and a method of assessing the anti-tumor efficacy of an unfinished drug. IS5183A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26375398 1998-09-17
JP10323374A JP2000159682A (en) 1998-09-17 1998-11-13 Crude drug antitumor activity enhancing method, antitumor activity enhancing crude drug-containing composition, antitumor efficacy evaluating method of crude drug treatment, and antitumor efficacy evaluating method of crude drug

Publications (1)

Publication Number Publication Date
IS5183A true IS5183A (en) 2000-03-17

Family

ID=26546176

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5183A IS5183A (en) 1998-09-17 1999-09-17 A method of enhancing the antineoplastic activity of unprocessed drugs, a mixture that enhances the anti-neoplastic activity of an unprocessed drug, a method of assessing the anti-neoplastic efficacy of the treatment of an unfinished drug, and a method of assessing the anti-tumor efficacy of an unfinished drug.

Country Status (19)

Country Link
JP (1) JP2000159682A (en)
KR (1) KR20000023206A (en)
CN (1) CN1255376A (en)
AU (1) AU4486299A (en)
BE (1) BE1012725A5 (en)
CA (1) CA2282234A1 (en)
DE (1) DE19944695A1 (en)
DK (1) DK199901235A (en)
ES (1) ES2155802B1 (en)
FR (2) FR2783426A1 (en)
GB (2) GB9920710D0 (en)
ID (1) ID23150A (en)
IL (1) IL131722A0 (en)
IS (1) IS5183A (en)
IT (1) IT1307267B1 (en)
NL (2) NL1013049C2 (en)
NO (1) NO994463L (en)
SE (2) SE9903307L (en)
SG (1) SG76631A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI300714B (en) * 2001-04-27 2008-09-11 Ajinomoto Kk Immunopotentiators
WO2002090559A1 (en) * 2001-05-07 2002-11-14 Biohub Co., Ltd. A method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby
JP4499979B2 (en) * 2001-05-21 2010-07-14 コンビ株式会社 Composition for controlling pathogen infection
EP1393738A4 (en) * 2001-06-01 2004-11-17 Ajinomoto Kk ANTIDIABETIC TREATMENT
KR100971599B1 (en) 2002-05-15 2010-07-20 비에이취엔 가부시끼가이샤 Compositions for the Prevention or Treatment of Vascular Associated Diseases
JP4826696B2 (en) * 2003-04-07 2011-11-30 ビーエイチエヌ株式会社 Angiogenesis inhibitors
JP4681801B2 (en) * 2002-05-15 2011-05-11 ビーエイチエヌ株式会社 Angiogenesis inhibitor and method for producing the same
JP2005089417A (en) * 2003-09-19 2005-04-07 Noevir Co Ltd Composition for prevention/treatment of diabetes
JP4587441B2 (en) * 2004-02-12 2010-11-24 株式会社クレハ Novel diabetes treatment and food
WO2006030750A1 (en) 2004-09-17 2006-03-23 Ssi Co., Ltd. Extract from agaricus blazei murrill capable of inhibiting breast cancer
JP2006273835A (en) * 2005-03-04 2006-10-12 Michishi Tani Malignant tumor therapeutic agent and food and drink containing the same
WO2011014729A1 (en) * 2009-07-31 2011-02-03 Yukiguni Maitake Co., Ltd. Maitake mushroom coffee
JPWO2011081024A1 (en) * 2009-12-29 2013-05-09 株式会社富士見養蜂園 Umami food and production method thereof
CN106309511A (en) * 2016-08-30 2017-01-11 青海民族大学 Effective part of agaricus gennadii for inhibiting CDC25 enzyme as well as preparation method and application of effective part
CN106333969A (en) * 2016-08-30 2017-01-18 青海民族大学 Agaricus gennadii HDAC1 enzyme inhibition effective part and preparation method and application
US20200397817A1 (en) * 2017-11-30 2020-12-24 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
KR102602787B1 (en) * 2020-12-16 2023-11-17 대한민국 Method for increasing the content of physiologically active ingredients and nutrients in Sparassis crispa
KR102646421B1 (en) * 2020-12-16 2024-03-12 대한민국 Method for increasing the content of physiologically active ingredients and nutrients in Grifola frondosa
KR102584680B1 (en) * 2020-12-17 2023-10-06 대한민국 Method for manufacturing tea of Lentinula edodes tea improved physiological activities and nutrition components

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276413A (en) * 1975-12-18 1977-06-27 Kureha Chem Ind Co Ltd Production of oncostatic substances
US4177108A (en) * 1977-03-02 1979-12-04 Tetsuro Ikekawa Process for producing emitanin
DE2842691A1 (en) * 1978-09-30 1980-04-10 Karl Dr Med Theurer Activation of pharmaceuticals by irradiation - using wavelengths corresp. to absorption maxima of the substance, opt. with the simultaneous application of magnetic field
JPS57206618A (en) * 1981-06-12 1982-12-18 Noda Shiyokukin Kogyo Kk Preparation of antitumor substance
JPH02203765A (en) * 1989-02-02 1990-08-13 Nippon Beet Sugar Mfg Co Ltd Food having antitumor function and production thereof
JP3357383B2 (en) * 1991-08-14 2002-12-16 昌宏 黒田 Low molecular weight plant composition
JP2955126B2 (en) * 1992-06-22 1999-10-04 笑代 丹羽 Pharmaceutical oleaginous preparation, food oleaginous preparation and production method thereof
US6015913A (en) * 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans

Also Published As

Publication number Publication date
ID23150A (en) 2000-03-23
NL1013049C2 (en) 2002-01-11
DK199901235A (en) 2000-03-18
GB9920710D0 (en) 1999-11-03
JP2000159682A (en) 2000-06-13
SE0100195D0 (en) 2001-01-24
ITTO990784A0 (en) 1999-09-14
FR2788697A1 (en) 2000-07-28
SG76631A1 (en) 2000-11-21
IT1307267B1 (en) 2001-10-30
ES2155802B1 (en) 2001-12-01
NL1019705A1 (en) 2002-01-29
NL1013049A1 (en) 2000-03-21
CN1255376A (en) 2000-06-07
ES2155802A1 (en) 2001-05-16
SE9903307D0 (en) 1999-09-16
BE1012725A5 (en) 2001-02-06
AU4486299A (en) 2000-03-30
DE19944695A1 (en) 2000-03-30
SE9903307L (en) 2000-03-18
IL131722A0 (en) 2001-03-19
NL1019705C2 (en) 2002-03-26
CA2282234A1 (en) 2000-03-17
ITTO990784A1 (en) 2001-03-14
NO994463D0 (en) 1999-09-15
GB2341800A (en) 2000-03-29
FR2783426A1 (en) 2000-03-24
SE0100195L (en) 2001-01-24
KR20000023206A (en) 2000-04-25
NO994463L (en) 2000-03-20
GB9921387D0 (en) 1999-11-10

Similar Documents

Publication Publication Date Title
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
NO20004654D0 (en) Gastroprotected omeprazole microgranules, method for obtaining such and pharmaceutical preparations
NO20052410D0 (en) Water-soluble iron carbobrate complexes, their production and drugs containing these complexes
PL362690A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
NO20005630D0 (en) Micro-laser spheres and structures, and associated methods
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
DK1066056T4 (en) Iron dextran compound for use as a component of a therapeutic agent for the prevention or treatment of iron deficiency, method of preparing the iron dextran compound and use of this compound for the manufacture of an ...
ZA200208492B (en) Game server, game machine under control of the server, and game control method.
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
IS6265A (en) 3 (5) -amino-pyrazole derivatives, a method for preparing them and the use of anti-tumor agents
NZ511201A (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
CZ20022079A3 (en) Fungicidal combinations of active substances, method of fighting fungi and use of such combinations of the active substances
NO20033440L (en) Treatment of neurological dysfunction including fructopyranose sulfamates and erythropoietin
WO2004089296A3 (en) Improved inhibitors for the soluble epoxide hydrolase
ZA200108012B (en) Method of enhancing the efficacy of anti-tumor agents.
IS1864B (en) New benzimidazole derivatives that treat stomach ulcers, methods for preparing them and pharmaceutical preparations containing them
NL1013049A1 (en) A method of enhancing the anti-tumor activity of crude drugs, a composition containing a crude drug having enhanced anti-tumor activity, a method of evaluating the effectiveness of the treatment of the crude drug on the anti-tumor activity, and a method of evaluating the anti-tumor activity of a crude drug.
MXPA03008582A (en) Agents and methods for treatment of cancer.
TR199801871A3 (en) Biphenylsulfonylcyanamides production method and their use as drugs.
DK1627631T3 (en) Morphine sulfate microgranules, process for their preparation and preparation comprising the same
RU2003102402A (en) METHOD FOR FORMING BILATERAL ENCLOSURE Pancreatoenteroanastomosis After Medial Pancreatic Resection
MXPA02002565A (en) Processes for making protein hydrolysates from animal peptone and for preserving mucosa.
NL1017117A1 (en) A method of enhancing the anti-tumor activity of an amygdaline-containing material, a composition containing an enhanced amygdaline-containing material, a method of evaluating the anti-tumor effectiveness of a treatment of amygdaline-containing material, and a method of evaluating amygdaline-containing anti-tumor material.
MXPA03006723A (en) Method for preventing and treating visceral pain and gastrointestinal disorders.
MXPA03006157A (en) Hormone replacement therapy method and its administration form.